This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

St. Jude Medical Reports Fourth Quarter And Full-Year 2012 Results

Non-GAAP Financial Measures

The Company provides adjusted net earnings and adjusted net earnings per share because St. Jude Medical management believes that in order to properly understand the Company’s short-term and long-term financial trends, investors may wish to consider the impact of certain adjustments (such as in-process research and development charges, impairment charges, restructuring charges, litigation charges or litigation reserve adjustments and income tax adjustments). These adjustments result from facts and circumstances (such as business development activities, restructuring activities, asset impairment events or developments, settlements and other developments relating to litigation and resolution of audits by tax authorities) that vary in frequency and impact on the Company’s results of operations. St. Jude Medical management uses adjusted net earnings and adjusted net earnings per share to forecast and evaluate the operational performance of the Company as well as to compare results of current periods to prior periods on a consolidated basis.

The Company provides constant currency sales growth because St. Jude Medical management believes that in order to properly understand the Company’s short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on net sales. St. Jude Medical management uses constant currency sales growth to forecast and evaluate the operational performance of the Company as well as to compare sales of current periods to prior periods.

Non-GAAP financial measures used by the Company may be calculated differently from, and therefore may not be comparable to, similarly titled measures used by other companies. Investors should consider non-GAAP measures in addition to, and not as a substitute for, or superior to, financial performance measures prepared in accordance with GAAP.

Conference Call/Webcast

St. Jude Medical’s fourth quarter and full-year 2012 earnings call can be heard live today beginning at 7 a.m. CST (also archived for 90 days) on the Investor Relations section of our website sjm.com.

Annual Investor Meeting

The company has scheduled an annual investor meeting for Friday, Feb. 1, 2013, in New York City. Investors must be registered in advance in order to gain entry into the meeting and can email Abbey Nelson, Investor Relations Specialist, at ANelson02@sjm.com for more information. The meeting will take place from approximately 8 a.m. to 12:30 p.m. EST, and the general public can listen to the meeting live on the Investor Relations section of our website sjm.com.

About St. Jude Medical

St. Jude Medical develops medical technology and services that focus on putting more control into the hands of those who treat cardiac, neurological and chronic pain patients worldwide. The company is dedicated to advancing the practice of medicine by reducing risk wherever possible and contributing to successful outcomes for every patient. St. Jude Medical is headquartered in St. Paul, Minn. and has four major focus areas that include: cardiac rhythm management, atrial fibrillation, cardiovascular and neuromodulation. For more information, please visit sjm.com.

Forward-Looking Statements

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. Such forward-looking statements include the expectations, plans and prospects for the Company, including potential clinical successes, anticipated regulatory approvals and future product launches, and projected revenues, margins, earnings and market shares. The statements made by the Company are based upon management’s current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include market conditions and other factors beyond the Company’s control and the risk factors and other cautionary statements described in the Company’s filings with the SEC, including those described in the Risk Factors and Cautionary Statements sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and Quarterly Report on Form 10-Q for the fiscal quarter ended September 29, 2012. The Company does not intend to update these statements and undertakes no duty to any person to provide any such update under any circumstance.

 
Summary of Fourth Quarter 2012 Sales and Reconciliation to Constant Currency Sales Growth
(in millions)
(unaudited)   4Q12 Sales   4Q11 Sales  

Reported % Change vs. 4Q11

 

Constant Currency % Change vs. 4Q11

 

Reported $ Change vs. 4Q11

 

Constant Currency $ Change vs. 4Q11

Total Sales   $1,372   $1,407   -2%   -1%   -$35   -$12
Total International Sales   $746   $771      
Total U.S. Sales   $626   $636                
Worldwide Cardiac Rhythm Management   $682   $728   -6%   -5%   -$46   -$35
International Cardiac Rhythm Management   $343   $377
U.S. Cardiac Rhythm Management   $339   $351                
Worldwide ICD   $422   $436   -3%   -2%   -$14   -$8
International ICD   $186   $199
U.S. ICD   $236   $237                
Worldwide Pacemakers   $260   $292   -11%   -9%   -$32   -$27
International Pacemakers   $157   $178
U.S. Pacemakers   $103   $114                
Worldwide Atrial Fibrillation   $239   $218   10%   11%   $21   $25
International Atrial Fibrillation   $148   $134
U.S. Atrial Fibrillation   $91   $84                
Worldwide Cardiovascular   $338   $340   0%   1%   -$2   $5
International Cardiovascular   $229   $234
U.S. Cardiovascular   $109   $106                
Worldwide Neuromodulation   $113   $121   -7%   -6%   -$8   -$7
International Neuromodulation   $26   $26
U.S. Neuromodulation   $87   $95
 
 
St. Jude Medical, Inc.
Condensed Consolidated Balance Sheets
(in millions)
(Unaudited)
   
December 29, 2012 December 31, 2011
Cash and cash equivalents $1,194 $986
Accounts receivable, net 1,349 1,367
Inventories 610 624
Other current assets 408 414
Property, plant & equipment, net 1,425 1,388
Goodwill 2,961 2,953
Other intangible assets, net 804 856
Other assets 400 417
Total assets $9,151 $9,005
 
Current debt obligations $530 $83
Other current liabilities 1,245 978
Long-term debt 2,550 2,713
Deferred income taxes, net 203 279
Long-term other liabilities 529 477
Total equity 4,094 4,475
Total liabilities & equity $9,151 $9,005
 
 
St. Jude Medical, Inc.
Condensed Consolidated Statements of Earnings
(in millions, except per share amounts)
(Unaudited)
           
 
Three Months Ended Year Ended
 
 
December 29, 2012 December 31, 2011 December 29, 2012 December 31, 2011
Net sales $1,372 $1,407 $5,503 $5,612
Cost of sales:
Cost of sales before special charges 372 374 1,445 1,486
Special charges 47 29 93 47
Total cost of sales 419 403 1,538 1,533
Gross profit 953 1,004 3,965 4,079
 
Selling, general & administrative expense 451 552 1,891 2,084
Research & development expense 158 177 676 705
Purchased in-process R & D charges 0 0 0 4
Special charges 119 118 298 171
 
Operating profit 225 157 1,100 1,115
Other income (expense), net (28) (24) (95) (96)
 
Earnings before income taxes 197 133 1,005 1,019
Income tax expense 77 8 253 193
Net earnings $120 $125 $752 $826
 
Adjusted net earnings (Non-GAAP) $285 (1) $274 (2) $1,095 (3) $1,074 (4)
 
Diluted net earnings per share $0.39 $0.39 $2.39 $2.52
Adjusted diluted net earnings per share (Non-GAAP) $0.92 (1) $0.86 (2) $3.48 (3) $3.28 (4)
 
Cash dividends declared per share $0.23 $0.21 $0.92 $0.84
 
Weighted average shares outstanding- diluted 310.0 320.0 314.8 327.1
 
 
(1) Fourth quarter 2012 adjusted net earnings and adjusted diluted net earnings per share exclude the following after-tax items totaling $159 or $0.51 per share:

- $75 charges, or $0.24 per share, primarily related to ongoing restructuring actions originally announced in August 2012 to realign our product divisions and to centralize certain support functions. The associated pre-tax amount of $106 was recorded as a Special Charge to Cost of sales ($8) and Special charges ($98).

- $11 charges, or $0.03 per share, related to intangible asset impairment charges and inventory write-offs for discontinued CATD product lines. The associated pre-tax amount of $17 was recorded as a Special Charge to Cost of sales ($14) and Special charges ($3).

- $27 charges, or $0.09 per share, related to litigation and other costs associated with field actions in our IESD business. The associated pre-tax amount of $43 was recorded as a Special Charge to Cost of sales ($25) and Special charges ($18).

- $46 income tax expense, or $0.15 per share, related to adjustments to uncertain tax positions associated with the effective settlement of certain income tax audits.

Fourth quarter 2012 adjusted net earnings and adjusted diluted net earnings per share include $6 of income tax benefit, or $0.02 per share, for the fourth quarter 2012 benefit relating to the federal research and development tax credit that was extended in 2013 retroactive to the beginning of the 2012 fiscal year.

 

(2) Fourth quarter 2011 adjusted net earnings and adjusted diluted net earnings per share exclude the following after-tax charges totaling $149 or $0.47 per share:

- $71 charges, or $0.22 per share, primarily related to ongoing restructuring actions that began in the second quarter to realign certain activities in our CRM business as well as employee termination and other costs primarily associated with continuing efforts to improve our sales & sales support organization. The associated pre-tax amount of $98 was recorded as a Special Charge to Cost of sales ($29) and Special charges ($69).

- $31 charges, or $0.10 per share, related to the write-down of certain intangible assets which were determined to be impaired. The associated pre-tax amount of $49 was recorded to Special charges.

- $38 charges, or $0.12 per share, related to increased collection risk for accounts receivable related to one customer in Europe. The associated pre-tax amount of $56 was recorded to SG&A expense.

- $9 charges, or $0.03 per share, related to contributions to the St. Jude Medical Foundation. The associated pre-tax amount of $15 was recorded to SG&A expense.
 
(3) Year ended 2012 adjusted net earnings and adjusted diluted net earnings per share exclude the following after-tax items totaling $321 or $1.02 per share:

- $123 charges, or $0.39 per share, primarily related to ongoing restructuring actions originally announced in August 2012 to realign our product divisions and to centralize certain support functions. The associated pre-tax amount of $173 was recorded as a Special Charge to Cost of sales ($10) and Special charges ($163).

- $11 charges, or $0.03 per share, related to intangible asset impairment charges and inventory write-offs for discontinued CATD product lines. The associated pre-tax amount of $17 was recorded as a Special Charge to Cost of sales ($14) and Special charges ($3).

- $75 charges, or $0.24 per share, primarily related to ongoing restructuring actions that began in 2011 to realign certain activities in our legacy CRM business as well as costs primarily associated with continuing efforts to improve our sales and sales support organizations. The associated pre-tax amount of $107 was recorded as a Special Charge to Cost of sales ($44) and Special charges ($63).

- $27 charges, or $0.09 per share, related to litigation and other costs associated with field actions in our IESD business. The associated pre-tax amount of $43 was recorded as a Special Charge to Cost of sales ($25) and Special charges ($18).

- $14 impairment charges, or $0.04 per share, related to writing down acquired neuromodulation intangible assets to fair value. The associated pre-tax amount of $23 was recorded to Special charges.

- $25 charges, or $0.08 per share, related to a license dispute settlement charge. The associated pre-tax amount of $28 was recorded to Special charges.

- $46 income tax expense, or $0.15 per share, related to adjustments to uncertain tax positions associated with the effective settlement of certain income tax audits.

Year ended 2012 adjusted net earnings and adjusted diluted net earnings per share include $22 of income tax benefit, or $0.07 per share, for the 2012 benefit relating to the federal research and development tax credit that was extended in 2013 retroactive to the beginning of the 2012 fiscal year.

 

(4) Year ended 2011 adjusted net earnings and adjusted diluted net earnings per share exclude the following after-tax charges totaling $248 or $0.76 per share:
- $19 charges, or $0.06 per share, related to AGA Medical Holdings, Inc. acquired inventory step up amortization expense. The associated pre-tax amount of $30 was recorded to Cost of sales.
- $121 charges, or $0.37 per share, primarily related to ongoing restructuring actions that began in the second quarter to realign certain activities in our CRM business as well as employee termination and other costs primarily associated with continuing efforts to improve our sales & sales support organization. The associated pre-tax amount of $169 was recorded as a Special Charge to Cost of sales ($47) and Special charges ($122).
- $31 charges, or $0.09 per share, related to the write-down of certain intangible assets which were determined to be impaired. The associated pre-tax amount of $49 was recorded to Special charges.
- $19 charges, or $0.06 per share, primarily related to post acquisition expenses for AGA Medical Holdings, Inc. which principally include contract termination costs and other integration costs in international locations. The associated pre-tax amount of $25 was recorded to SG&A expense.
- $9 charges, or $0.03 per share, related to contributions to the St. Jude Medical Foundation. The associated pre-tax amount of $15 was recorded to SG&A expense.
- $46 charges, or $0.14 per share, related to increased collection risk for accounts receivable related to customers in Europe. The associated pre-tax amount of $66 was recorded to SG&A expense.
- $3 Purchased in-process R&D charges, or $0.01 per share, associated with the Company's acquisition of certain pre-development technology assets.
 
 
2013 Earnings Guidance Reconciliation
       
First Quarter 2013 Full Year 2013
 
Estimated 2013 diluted net earnings per share $0.95 - $ 0.97 $3.61 - $ 3.66
Restructuring actions 0.04 (5) 0.15 (5)
Federal R&D tax credit extension (0.08) (6) (0.08) (6)
Estimated 2013 adjusted diluted net earnings per share (Non-GAAP) $0.91 - $ 0.93 $3.68 - $ 3.73
 

(5) The Company's above estimated 2013 adjusted diluted net earnings per share (Non-GAAP) excludes the impact of after-tax charges expected to be recognized related to ongoing business restructuring actions.

 

(6) The federal research and development tax credit was extended in 2013 retroactive to the beginning of the 2012 fiscal year. The Company's above estimated 2013 adjusted diluted net earnings per share (Non-GAAP) excludes the tax benefit related to fiscal year 2012 expected to be recognized in the first quarter of 2013.

 





4 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,039.49 +60.36 0.36%
S&P 500 1,992.37 +5.86 0.30%
NASDAQ 4,532.1040 +5.6220 0.12%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs